SynthesisBMC endocrine disorders2025
A comprehensive compilation of data on the association between XRCC3 polymorphisms and thyroid cancer susceptibility.
Synthesis in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolymorphisms in the XRCC3 gene, a key component of homologous recombination repair, have been studied for their potential role in thyroid cancer susceptibility. However, published findings remain inconsistent across populations and genetic variants. This meta-analysis aimed to clarify the associations between XRCC3 polymorphisms and thyroid cancer risk, with emphasis on variant- and ethnicity-specific effects.
methodsA systematic search of PubMed, EMBASE, Scopus, CNKI, and other databases up to July 10, 2025 identified case-control studies reporting genotype distributions of XRCC3 polymorphisms in thyroid cancer. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated under fixed- or random-effects models. Subgroup analyses by ethnicity, sensitivity tests, and publication bias assessments (Egger's and Begg's tests) were performed.
resultsTwenty-four eligible studies were included: 14 for rs861539, six for rs1799796, and four for rs1799794, comprising 4,502 cases and 6,048 controls. For rs861539, no significant association with thyroid cancer risk was observed in the overall population (T vs. C: OR = 1.089, 95% CI = 0.908-1.306, p = 0.358), with consistent null results across Asian and Caucasian subgroups. For rs1799796, no overall association was detected (G vs. A: OR = 0.970, 95% CI = 0.875-1.075, p = 0.558), but a protective effect emerged in Asian populations (GA vs. AA: OR = 0.835, 95% CI = 0.701-0.995, p = 0.043). For rs1799794, significant associations were found under recessive models (GG vs. AA: OR = 1.371, 95% CI = 1.066-1.762, p = 0.014; GG vs. GA + AA: OR = 1.316, 95% CI = 1.037-1.669, p = 0.024). Considerable heterogeneity was observed (I² = 42.2-93.3%), and eight studies deviated from Hardy-Weinberg equilibrium.
conclusionsXRCC3 rs1799794 polymorphism is associated with increased thyroid cancer risk, particularly under recessive genetic models. The rs1799796 variant may confer a protective effect in Asian populations, whereas rs861539 shows no significant association. These results highlight population-specific genetic effects and underscore the importance of considering ethnicity in genetic association studies. Further large, well-designed investigations are warranted to confirm these findings and to explore potential gene-environment interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.